Business
AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico
Study will provide real-world data to evaluate the effectiveness of bamlanivimab in reducing COVID-19 hospitalizations in a high-risk population VANCOUVER,
About this update from Abcellera Biologics Inc.
[{"type":"text","content":"\nStudy will provide real-world data to evaluate the effectiveness of bamlanivimab in reducing COVID-19 hospitalizations in a high-risk population\n\n VANCOUVER, British Columbia--(BUSINESS WIRE)--\nAbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody developed through AbCellera’s collaboration with Eli Lilly and Company (Lilly), will be evaluated in a new pragmatic study in high-risk patients with COVID-19. Lilly’s trial, in collaboration with the state of New Mexico and major local institutions, will collect data on the effectiveness and safety of bamlanivimab in a real-world setting that includes a diverse population and spans both rural and urban environments. As part of this study, Lilly will employ its unique mobile research units used successfully in other studies. Additional details regarding the new trial can be found here.\n\n“By deploying on-site infusion clinics, Lilly continues to lead in finding ways to bring antibody treatments to patients,” said Carl Hansen, Ph.D., CEO of AbCellera. “We applaud their continued innovation and tireless efforts in fighting the COVID-19 pandemic.”\n\nBamlanivimab is currently authorized in the United States and Canada for the treatment of mild to moderate COVID-19 patients who are at high risk for progressing to severe COVID-19 and/or hospitalization. Both the Emergency Use Authorization (EUA) granted by the U.S. Food and Drug Administration and the interim authorization granted by Health Canada under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 are based on data from BLAZE-1, a randomized, double-blind placebo-controlled Phase 2 study in patients with recently diagnosed mild to moderate COVID-19 in the outpatient setting. Data from BLAZE-1 showed bamlanivimab reduced viral load, symptoms, and hospitalizations.\n\nAbCellera’s COVID-19 response was based on capabilities developed over the past two years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of P3 is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen.\n\nAbout Bamlanivimab\n\nBamlanivimab is a recombinant, neutralizing human IgG1 monoc...